Michael Morelli on Retatrutide: Fact Check
Michael Morelli, a fitness coach and social media personality, posted a video titled "What I Learned After 60 Days on Retatrutide (Not Just Fat Loss)" where he describes his personal experience using retatrutide and makes a series of claims about its mechanism, muscle-building properties, cognitive effects, and metabolic benefits. He also promotes a grey market peptide source and describes using a non-standard dosing protocol.
This page fact-checks his major claims against published clinical trial data, peer-reviewed research, and regulatory information.
The Triple Agonist Mechanism
Morelli describes retatrutide as a "triple agonist" targeting GLP-1, GIP, and glucagon receptors simultaneously. He explains that GLP-1 reduces appetite and stabilizes blood sugar, GIP supports fat metabolism and glucose control, and glucagon boosts fat oxidation and increases resting energy expenditure.
| Claim | Published Data | Verdict |
|---|---|---|
| Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon | Correct. Retatrutide (LY3437943) is a single-molecule triple agonist that activates GLP-1, GIP, and glucagon receptors. Jastreboff et al. (2023), NEJM. | Accurate |
| GLP-1 reduces appetite, stabilizes blood sugar, and enhances insulin sensitivity | GLP-1 receptor activation does reduce appetite via central satiety pathways, improves glycemic control, and enhances insulin secretion in a glucose-dependent manner. Well-established pharmacology. | Accurate |
| GIP supports fat metabolism and improves glucose control | GIP receptor activation enhances insulin secretion and may improve lipid metabolism. Its exact role in fat metabolism is still being studied, but tirzepatide (GLP-1/GIP dual agonist) data supports metabolic benefits. | Accurate |
| Glucagon receptor activation boosts fat oxidation and increases resting energy expenditure | Glucagon receptor activation increases hepatic glucose output, promotes fatty acid oxidation, and increases energy expenditure. Phase 2 retatrutide data showed increased resting energy expenditure vs placebo. This is the key differentiator from dual agonists. | Accurate |
Morelli\u0027s description of the triple agonist mechanism is broadly correct. He identifies the three receptor targets and their general metabolic roles accurately. This is the strongest part of his video from a factual standpoint.
For a detailed mechanism breakdown, see How Retatrutide Works.
"This Stuff Is Anabolic" — Muscle Preservation Claims
Morelli makes the bold claim that retatrutide is "anabolic" and that users "won\u0027t lose muscle like you do on the semaglutides and the tirzepatides." Later in the video he states: "Imagine dropping body fat, maintaining or even adding lean muscle."
| Claim | Published Data | Verdict |
|---|---|---|
| Retatrutide is anabolic | No clinical trial has demonstrated anabolic (muscle-building) effects from retatrutide. The Phase 2 DXA body composition substudy (Coskun et al., Lancet Diabetes Endocrinol 2025) showed retatrutide still causes lean mass loss, though proportionally less than total weight loss. | Significantly overstated |
| You won't lose muscle on retatrutide like semaglutide/tirzepatide | The Phase 2 body composition substudy showed approximately 75-80% of weight lost came from fat mass and 20-25% from lean mass. This is a favorable ratio compared to semaglutide (where lean mass can account for 25-39% of weight lost in some studies), but lean mass loss still occurs. | Overstated |
| You can maintain or even add lean muscle on retatrutide | No published clinical trial has shown lean mass gain with retatrutide treatment. All weight loss interventions result in some lean mass loss. The glucagon component may help preserve lean mass relative to fat mass, but adding muscle while in caloric deficit from retatrutide has not been demonstrated. | Not supported by data |
This is the most misleading section of the video. Calling retatrutide "anabolic" implies it builds muscle, which is not what any clinical data shows. While retatrutide\u0027s body composition profile is genuinely more favorable than semaglutide — with proportionally more fat loss — participants in every dose group still lost lean mass. The claim that you can "add lean muscle" on retatrutide contradicts the published data.
For the full body composition data, see Retatrutide and Muscle Loss.
Cognitive Clarity and "Flow State" Claims
Morelli claims he noticed "cognitive function and clarity" from the very first injection, that "brain fog disappears," and that retatrutide creates a "flow state feeling" through improved dopamine and neurotransmitter balance.
| Claim | Published Data | Verdict |
|---|---|---|
| Cognitive clarity from the first injection | No published retatrutide trial has measured cognitive endpoints. The Phase 2 (NEJM 2023) and Phase 3 TRIUMPH trials measured weight, glycemic markers, and safety — not cognitive function. Any perceived cognitive effect from a single injection would be consistent with placebo response. | Not supported by data |
| Brain fog disappears due to stable blood sugar and improved insulin function | While GLP-1 receptor agonists have been studied for neuroprotective effects (primarily semaglutide in Alzheimer's research), no retatrutide-specific cognitive data exists. The theoretical link between blood sugar stability and cognitive function is plausible but has not been tested with retatrutide. | Speculative |
| Retatrutide improves dopamine and neurotransmitter balance | GLP-1 receptors exist in the brain and preclinical studies suggest GLP-1 agonists may influence reward pathways. However, no published human study has measured retatrutide's effects on dopamine or neurotransmitter levels. | Speculative |
| Creates a flow state feeling | No clinical evidence supports this claim. "Flow state" is a subjective experience that has not been measured in any retatrutide trial. | Not supported by data |
None of Morelli\u0027s cognitive claims are supported by published clinical data. While there are plausible biological mechanisms — GLP-1 receptors are present in the brain, and stable blood glucose can improve concentration — no retatrutide trial has measured cognitive endpoints. Anecdotal reports of mental clarity are common across many interventions and are consistent with placebo effects, reduced caloric intake, or improved sleep from weight loss.
Retatrutide "Increases Energy Expenditure"
Morelli claims that unlike other weight loss drugs which "lower metabolism over time," retatrutide "actually increases energy expenditure." He positions this as a unique advantage over semaglutide and tirzepatide.
| Claim | Published Data | Verdict |
|---|---|---|
| Retatrutide increases energy expenditure | The glucagon receptor component of retatrutide does increase resting energy expenditure. Phase 2 data showed a statistically significant increase in resting energy expenditure vs placebo. This is a real and meaningful effect of glucagon receptor activation. | Accurate |
| Other weight loss peptides lower metabolism over time | Metabolic adaptation (reduced energy expenditure) occurs with any sustained weight loss, regardless of the method. However, semaglutide and tirzepatide studies show resting metabolic rate decreases roughly in proportion to weight lost — not dramatically below expected levels. The framing that other drugs actively "lower metabolism" is misleading. | Overstated |
| This makes retatrutide unique compared to semaglutide and tirzepatide | The glucagon component is a genuine differentiator. Semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP) do not activate the glucagon receptor and do not show the same energy expenditure increase. This is one of the key theoretical advantages of triple agonism. | Accurate |
The core claim about energy expenditure is accurate — glucagon receptor activation does increase resting energy expenditure, and this is supported by Phase 2 data. However, Morelli\u0027s framing that other GLP-1 drugs actively "lower metabolism" is misleading. All weight loss causes some metabolic adaptation, but semaglutide and tirzepatide do not cause pathological metabolic suppression.
"Rapid Fat Loss Without Muscle Loss" and Non-Standard Dosing
Morelli claims retatrutide produces "rapid fat loss without muscle loss" and states that he doses his clients differently from physicians: "I am not dosing it the same way that these physicians and doctors are dosing it. I\u0027m doing it way different for my guys."
| Claim | Published Data | Verdict |
|---|---|---|
| Rapid fat loss without muscle loss | Phase 2 data (Jastreboff et al., NEJM 2023) showed up to 24.2% weight loss at 48 weeks at the 12 mg dose. TRIUMPH-4 showed 28.7% at 68 weeks. However, the body composition substudy confirmed lean mass loss occurs — approximately 20-25% of total weight lost was lean mass. "Without muscle loss" is incorrect. | Overstated |
| Non-standard dosing produces better results | The Phase 3 TRIUMPH program used a carefully designed titration schedule (2 mg → 4 mg → 8 mg → 12 mg over 16-20 weeks) developed through clinical trials to balance efficacy and tolerability. No published evidence supports alternative dosing protocols. Using non-standard doses from grey market peptides introduces unknown risks. | Not supported by data |
| His clients are getting stronger and dropping body fat simultaneously | Individual anecdotal reports cannot be verified and do not constitute clinical evidence. Strength gains during weight loss are possible with resistance training regardless of pharmacotherapy. These results cannot be attributed to retatrutide or to his specific dosing protocol without controlled study. | Unverifiable |
Morelli is not a physician, and promoting non-standard dosing protocols for an investigational drug that has not been FDA-approved is concerning. The clinical trial titration schedule was designed to minimize gastrointestinal side effects while achieving therapeutic doses. Deviating from studied protocols introduces unknown safety risks.
For the evidence-based dosing protocol, see Retatrutide Dosage Guide.
Grey Market Peptide Sources
Morelli claims his peptide source produces the same quality as compounding pharmacies and encourages viewers to contact him for the source. He states: "The source that I get it from makes the same peptides for both the research only peptide places and the compounding pharmacies."
| Claim | Published Data | Verdict |
|---|---|---|
| Research peptide sources produce the same quality as compounding pharmacies | Compounding pharmacies in the US are regulated by state boards of pharmacy and must follow USP standards for sterility and potency. Research peptide companies sell products labeled "not for human consumption" and are not subject to the same regulatory oversight. Multiple FDA warning letters have documented contamination, underdosing, and mislabeling in research peptide products. | Misleading |
| Labs, purity, and potency reports guarantee quality | Third-party certificates of analysis (COAs) from research peptide vendors can be fabricated or outdated. Compounding pharmacies must pass state inspections and follow standardized testing protocols. A COA from an unregulated vendor does not carry the same assurance as pharmacy-grade quality control. | Misleading |
| Compounding pharmacy products can be weak and underdosed | Quality issues have occurred at some compounding pharmacies, and the FDA has taken enforcement actions against non-compliant facilities. However, this does not make unregulated research peptides a safer alternative — it makes proper pharmacy selection important. | Cherry-picked |
Retatrutide is an investigational drug that has not been FDA-approved. It is not legally available for human use outside of clinical trials. Grey market research peptides carry real risks including contamination, incorrect dosing, endotoxin presence, and degradation from improper storage. Morelli is not a licensed pharmacist or physician, and promoting unregulated peptide sources raises serious safety and legal concerns.
For more on the risks of grey market peptides, see Grey Market Retatrutide.
Frequently Asked Questions
Who is Michael Morelli?
Michael Morelli is a fitness coach and social media personality who promotes peptide use, training programs, and nutrition coaching. He is not a physician, pharmacist, or licensed medical professional. He describes himself as being 44 years old and at approximately 11.5% body fat in this video. He sells coaching services that include peptide protocols using grey market sources.
Is retatrutide actually anabolic?
No. No clinical trial has demonstrated anabolic (muscle-building) effects from retatrutide. The Phase 2 body composition substudy (Coskun et al., Lancet Diabetes Endocrinol 2025) showed that while retatrutide has a favorable fat-to-lean mass loss ratio — approximately 75-80% of weight lost came from fat — lean mass loss still occurs. Retatrutide is a weight loss drug, not an anabolic agent. For the full data, see Retatrutide and Muscle Loss.
Does retatrutide improve cognitive function?
There is no published clinical evidence that retatrutide improves cognitive function, reduces brain fog, or enhances focus. While GLP-1 receptor agonists are being studied for neuroprotective effects (primarily semaglutide in Alzheimer\u0027s trials), no retatrutide trial has measured cognitive endpoints. Any perceived cognitive improvements may be attributable to placebo effects, better sleep from weight loss, or improved blood glucose stability.
Is it safe to buy retatrutide from a non-pharmacy source?
Retatrutide is an investigational drug that has not been FDA-approved for any use. Grey market research peptides are sold as "not for human consumption" and are not subject to the same quality controls as pharmaceutical products. Risks include contamination, inaccurate dosing, endotoxin presence, and degradation from improper handling. The FDA has issued multiple warning letters to research peptide vendors. For a detailed risk analysis, see Grey Market Retatrutide.
Does retatrutide really increase energy expenditure?
Yes, this is one of Morelli\u0027s accurate claims. The glucagon receptor component of retatrutide increases resting energy expenditure, which has been confirmed in Phase 2 clinical data. This is a genuine differentiator from semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP), which do not activate the glucagon receptor. For more on how the three receptors work, see How Retatrutide Works.
Sources
- Morelli, M. (2025). "What I Learned After 60 Days on Retatrutide (Not Just Fat Loss)." Watch on YouTube
- Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
- Coskun, T., et al. (2025). Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2 trial. The Lancet Diabetes & Endocrinology, 13(8), 674-684. DOI: 10.1016/S2213-8587(25)00092-0
- Eli Lilly and Company. (2025). TRIUMPH-4 topline results: Retatrutide achieved significant weight loss and improved knee osteoarthritis pain. Press release
- FDA. (2023-2025). Warning letters to compounding pharmacies and research peptide vendors regarding GLP-1 receptor agonist products. FDA.gov
Medical Disclaimer
The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency.
Michael Morelli is not a physician or licensed medical professional. He is a fitness coach promoting grey market peptide use and non-standard dosing protocols that have not been studied in clinical trials. His video contains a mix of accurate mechanism information and significantly overstated claims about muscle building, cognitive enhancement, and grey market peptide safety.
Do not use this information to make decisions about your health without consulting a qualified healthcare provider. Do not purchase or self-administer investigational drugs from unregulated sources.
This site is not affiliated with Michael Morelli, Eli Lilly and Company, or any pharmaceutical manufacturer.
Sources
- What I Learned After 60 Days on Retatrutide (YouTube)
YouTube
- Phase 2 trial (NEJM)
New England Journal of Medicine
- Body composition substudy (Lancet)
The Lancet Diabetes & Endocrinology
Related reading
Does Retatrutide Cause Muscle Loss?
The first DXA body composition data for retatrutide, the glucagon muscle-sparing hypothesis, and evidence-based strategies to preserve lean mass.
Grey Market Retatrutide: Risks, Dangers, and What You Should Know
Grey market retatrutide is unregulated, untested, and potentially dangerous. Here's what the data shows and how to access it safely.
Retatrutide Dosage & Dosing Guide
How retatrutide is dosed in clinical trials — titration schedule, dose levels, and what each dose achieved.
How Does Retatrutide Work? Mechanism of Action Explained
The world's first triple agonist explained — how GLP-1, GIP, and glucagon receptors work together to reduce appetite and increase energy expenditure.